ArticleJournal of occupational medicine and toxicology (London, England)2016
Hepatitis C among healthcare personnel: secondary data analyses of costs and trends for hepatitis C infections with occupational causes.
Article in Journal of occupational medicine and toxicology (London, England), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Hepatitis B and C virus infection among healthcare workers in Africa: a systematic review and meta-analysis.Environmental health and preventive medicine · 2021Pooled it
- Occupational Infections among Dental Health Workers in Germany-14-Year Time Trends.International journal of environmental research and public health · 2021Article
- Hepatitis C in healthcare personnel: follow-up analysis of treatments with direct-acting antiviral agents.Journal of occupational medicine and toxicology (London, England) · 2021Article
- Survival-Day @ Wiesbaden business school - evaluation of a short-term educational intervention to reduce work-associated health risks during nursing internships of students in health care economics.Journal of occupational medicine and toxicology (London, England) · 2019Article
- Infections in Healthcare Workers in Germany-22-Year Time Trends.International journal of environmental research and public health · 2018Article
- [Human hantavirus infections].Zentralblatt fur Arbeitsmedizin, Arbeitsschutz und Ergonomie · 2018Review
- Hepatitis C in healthcare personnel: secondary data analysis of therapies with direct-acting antiviral agents.Journal of occupational medicine and toxicology (London, England) · 2018Article
- An index to characterize female career promotion in academic medicine.Journal of occupational medicine and toxicology (London, England) · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatitis C infection is a global public health issue. Chronic hepatitis C infection is associated with significant morbidity and mortality. The aim of this study is to describe the costs for occupationally-cased hepatitis C infections based on data from an accident insurance carrier.
methodsThis study is a secondary analysis based on the Database of a German Institution for Statutory Accident Insurance. The analysis is based on a sample of insured parties whose hepatitis C infections were recorded as occupational diseases between 1996 and 2013. The analysis is based on recognised hepatitis C cases and incorporates records registered between 1 January 2000 and 31 December 2014.
resultsWithin the study period, the number of reported and recognised hepatitis C cases declined by 73 and 86% respectively. The majority of recognised hepatitis C cases (
conclusionsFor hepatitis C infections as an occupational disease, a considerable increase in costs has been observed in recent years, while the number of reports has declined heavily. This rise in costs is explained by the increase in pension payments and, since 2012, by a rise in the costs for drugs. The high costs of anti-viral therapies is offset by the potential for considerable treatment benefits. Healing the infection is expected to generate long-term cost savings for statutory accident insurance carriers, and also for social security systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.